Last reviewed · How we verify
Post-Op pregabalin
Post-Op pregabalin is a Small molecule drug developed by Nevakar, Inc.. It is currently in Phase 2 development.
Pregabalin is a small molecule that modulates voltage-gated calcium channels. It has been studied in clinical trials for various foot and ankle conditions, including bunion, bunionette, hammertoe, ankle fractures, and Achilles tendon surgery.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Post-Op pregabalin |
|---|---|
| Sponsor | Nevakar, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multimodal Versus Opioid aNalgesia in carDiAc Surgery (PHASE4)
- Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study
- Dental Pain Study of Analgesics in Patients Undergoing Molar Removal (PHASE2)
- Pregabalin and Post-thoracotomy Pain (PHASE4)
- Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Post-Op pregabalin CI brief — competitive landscape report
- Post-Op pregabalin updates RSS · CI watch RSS
- Nevakar, Inc. portfolio CI
Frequently asked questions about Post-Op pregabalin
What is Post-Op pregabalin?
Who makes Post-Op pregabalin?
What development phase is Post-Op pregabalin in?
Related
- Manufacturer: Nevakar, Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing